Literature DB >> 3769295

Orthopedic experience with methicillin-resistant Staphylococcus aureus during a hospital epidemic.

K D Johnson, D W Johnston.   

Abstract

Thirty-eight orthopedic patients with proven methicillin-resistant Staphylococcus aureus (MRSA) infections were assessed as to the effectiveness of treatment. All patients were admitted between June 1981 and September 1983 and were among the 508 patients who had positive cultures for MRSA during that period. The average age of the patients was 32.5 years. Thirty-two patients had fractures. In 70% of the patients the injury was due to a motor vehicle accident. Sixty percent of the patients had Grade III open fractures with severe soft tissue injury or associated vascular injury. All patients were given antibiotics within 30 days of a positive culture, with 97% getting a first-generation cephalosporin. There were an average of 5.5 surgical procedures per patient (range, one to 16). Nine patients (24%) required amputation and eight (21%) lost joints either by excision or fusion. Only 14 patients (37%) healed without drainage. Four patients (10%) healed the original fracture or surgery with chronic drainage. There were three nonunions, two of which continue to drain. The antibiotic cost for Vancomycin alone increased 300%, from $2,000 in 1982 to approximately $680,000 in 1983. Methicillin-resistant in 1983. Methicillin-resistant S. aureus (MRSA) has significant epidemic potential. Infection with this organism carries a high-morbidity in order to control the organism. Any reported case of MRSA should be isolated quickly and thoroughly investigated epidemiologically in an attempt to prevent an epidemic. Vancomycin is the antibiotic of choice. Emphasis should be placed on the interruption of transmission of MRSA within and among hospitals. Serious consideration must be given to the long-term effects of prophylactic antibiotics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769295

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

Review 1.  [Prevention of infection in the current treatment of open fractures: an evidence-based systematic analysis].

Authors:  S Grote; H Polzer; W C Prall; S Gill; S Shafizadeh; M Banerjee; B Bouillon; H Bäthis
Journal:  Orthopade       Date:  2012-01       Impact factor: 1.087

2.  What is the rate of methicillin-resistant Staphylococcus aureus and Gram-negative infections in open fractures?

Authors:  Antonia F Chen; Verena M Schreiber; Wesley Washington; Nalini Rao; Andrew R Evans
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

3.  Penetration of linezolid into rabbit intervertebral discs and surrounding tissues.

Authors:  Miki Komatsu; Masahiko Takahata; Mitsuru Sugawara; Yoh Takekuma; Takashi Kato; Manabu Ito; Yuichiro Abe; Tohru Irie; Norimasa Iwasaki; Akio Minami
Journal:  Eur Spine J       Date:  2010-08-09       Impact factor: 3.134

4.  Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Strategy to control methicillin-resistant Staphylococcus aureus post-operative infection in orthopaedic surgery.

Authors:  J C De Lucas-Villarrubia; M Lopez-Franco; J J Granizo; J C De Lucas-Garcia; E Gomez-Barrena
Journal:  Int Orthop       Date:  2003-05-15       Impact factor: 3.075

6.  Antimicrobial Activity of 3D-Printed Poly(ε-Caprolactone) (PCL) Composite Scaffolds Presenting Vancomycin-Loaded Polylactic Acid-Glycolic Acid (PLGA) Microspheres.

Authors:  Zhi Zhou; Qingqiang Yao; Lan Li; Xin Zhang; Bo Wei; Li Yuan; Liming Wang
Journal:  Med Sci Monit       Date:  2018-09-30

7.  Bacterial infection and antibiotic resistance pattern in open fracture cases in Indonesia.

Authors:  Ahmad Taufik; Adnanto Wiweko; Didit Yudhanto; E Hagni Wardoyo; Philip Habib; Mohammad Rizki; Rohadi Muhammad Rosyidi
Journal:  Ann Med Surg (Lond)       Date:  2022-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.